Acceleron Pharma

Investors/Media

Press Releases

Date Title and Summary View
Toggle Summary Acceleron Announces Luspatercept Phase 3 MEDALIST and BELIEVE Presentations Selected for “Best of ASH” by the American Society of Hematology
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 5, 2018-- Acceleron Pharma Inc. (Nasdaq:XLRN) today announced that the presentations of the MEDALIST and BELIEVE Phase 3 trial results of luspatercept in patients with lower-risk myelodysplastic syndromes (MDS) and beta-thalassemia associated anemias,
View HTML
Toggle Summary Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 MEDALIST Trial Evaluating Luspatercept in Patients with Myelodysplastic Syndromes at the ASH 2018 Plenary Session
Pivotal phase 3 data demonstrated treatment with investigational luspatercept resulted in statistically significant increased red blood cell transfusion independence compared to placebo Regulatory submissions planned in the United States and Europe in the first half of 2019 SUMMIT, N.J.
View HTML
Toggle Summary Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 BELIEVE Trial Evaluating Luspatercept in Adult Patients with Beta-Thalassemia at ASH 2018
Pivotal phase 3 data demonstrated treatment with investigational luspatercept resulted in significant reduction of transfusion burden compared to placebo Regulatory submissions planned in the United States and Europe in the first half of 2019 SUMMIT, N.J. & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec.
View HTML
Toggle Summary Acceleron Receives FDA Fast Track Designation for ACE-083 in Charcot-Marie-Tooth Disease
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 28, 2018-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration ( FDA ) has
View HTML
Toggle Summary Acceleron to Host Conference Call and Webcast to Review MEDALIST and BELIEVE Phase 3 Trial Presentations of Luspatercept at the 60th American Society of Hematology Annual Meeting
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 27, 2018-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced it will host a conference call and live audio webcast on Monday,
View HTML
Toggle Summary Acceleron to Participate in Two Upcoming Healthcare Investor Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 26, 2018-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that senior management will participate in two upcoming
View HTML
Toggle Summary Acceleron Announces Preclinical Presentations on Sotatercept in Pulmonary Arterial Hypertension at the 2018 American Heart Association Scientific Session
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 7, 2018-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced plans to deliver three preclinical presentations on sotatercept
View HTML
Toggle Summary Acceleron Announces that Phase 3 Results from the MEDALIST and BELIEVE Trials of Luspatercept will be Presented at the 60th American Society of Hematology Annual Meeting
– Phase 3 MEDALIST trial results to be presented in Plenary Scientific Session – – Phase 3 BELIEVE trial results to be shared in oral presentation – – Acceleron to hold conference call and webcast live from ASH, December 3 , at 9:00 a.m. EST – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov.
View HTML
Toggle Summary Acceleron Reports Third Quarter 2018 Operating and Financial Results
– MEDALIST and BELIEVE Phase 3 trial results in myelodysplastic syndromes (MDS) and beta-thalassemia, respectively, are expected to be presented at the 60 th American Society of Hematology (ASH) Annual Meeting – – COMMANDS Phase 3 trial in patients with lower-risk MDS who are treatment naïve has
View HTML
Toggle Summary Acceleron to Webcast Third Quarter 2018 Operating and Financial Results on October 30, 2018
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 23, 2018-- Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Tuesday, October 30, 2018 at 4:30 p.m. EDT to discuss its third quarter 2018 operating and financial results.
View HTML